Evidence map›Paper›PMID 40489964›Full record

ArticleAmerican journal of nephrology2026

Inhibition of Calcium Release-Activated Calcium Channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE Study a Randomized Trial.

Lakhmir S Chawla, Patrick T Murray, Stuart L Goldstein, Andrew Cunningham, Sudarshan Hebbar, Richard G Wunderink, Glenn M Chertow

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06374797 (Auxora for the Treatment of AKI and Modulation of Injurious "Crosstalk" With the Lung), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06374797 phase2active not recruitingnot on this map

Auxora for the Treatment of AKI and Modulation of Injurious "Crosstalk" With the Lung: A Randomized Control Trial (KOURAGE)

TypeinterventionalSponsorCalciMedica, Inc.Ran2024 to 2026Enrolled150ConditionsAcute Kidney InjuryArmsAuxora, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lakhmir S ChawlaVeterans Affairs Medical Center, San Diego, California, USA.
Patrick T MurraySchool of Medicine, University College Dublin, Dublin, Ireland.
Stuart L GoldsteinUniversity of Cincinnati College of Medicine, Center for Acute Care Nephrology Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Andrew CunninghamCalciMedica, Inc., La Jolla, California, USA.
Sudarshan HebbarCalciMedica, Inc., La Jolla, California, USA.
Richard G WunderinkNorthwestern University Feinberg School of Medicine, Division of Pulmonary and Critical Care Medicine, Chicago, Illinois, USA.
Glenn M ChertowDepartments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California, USA, gchertow@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Patients with severe acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) experience poorer outcomes, including higher rates of in-hospital mortality, relative to patients with less severe AKI, or those without associated AHRF. Zegocractin is a calcium release-activated calcium (CRAC) channel inhibitor with potent anti-inflammatory and pulmonary endothelial protective properties. Preclinical and early phase clinical studies suggest that zegocractin may be an effective agent for the treatment of AKI. Methods: KOURAGE (NCT06374797) is a multicenter, phase 2, randomized, double blind, placebo-controlled trial that aims to enroll approximately 150 patients with severe AKI and AHRF. Eligible patients will be randomized 1:1 to receive a total of five daily doses of zegocractin intravenous emulsion (Auxora™) or matching placebo. The objective was to evaluate the safety and efficacy of Auxora in patients with severe AKI, with the primary efficacy endpoint defined as the number of days alive, ventilator-free and kidney replacement therapy-free from the start of the first infusion of the study drug through day 30. A key secondary efficacy endpoint is the proportion of patients with major adverse kidney events at day 90. Conclusion: The KOURAGE trial will investigate the safety and efficacy of Auxora in patients with severe AKI and AHRF. </p>.

Indexed as

Acute Kidney InjuryCalcium Channel BlockersCalcium Release Activated Calcium ChannelsRespiratory InsufficiencyAdultClinical Trials, Phase II as TopicDouble-Blind MethodFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeCalcium Channel BlockersCalcium Release Activated Calcium ChannelsAcute hypoxemic respiratory failureAcute kidney injuryAuxoraCRAC channel inhibitorZegocractin

Identifiers

PMID40489964
PMCPMC12240565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.